|
gptkbp:instanceOf
|
gptkb:cancer
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
specialized medical centers
|
|
gptkbp:antigen
|
gptkb:CD19
gptkb:BCMA
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:category
|
precision medicine
adoptive cell transfer
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Phase_I
Phase II
Phase III
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:developedBy
|
2010s
|
|
gptkbp:firstApprovedIndication
|
gptkb:pediatric_acute_lymphoblastic_leukemia
|
|
gptkbp:fullName
|
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CAR-T therapy
|
|
gptkbp:inventedBy
|
gptkb:Carl_June
gptkb:Michel_Sadelain
|
|
gptkbp:limitation
|
high cost
limited efficacy in solid tumors
complex manufacturing process
|
|
gptkbp:mechanismOfAction
|
genetically engineered T cells target cancer cells
|
|
gptkbp:notableProduct
|
gptkb:Abecma
gptkb:Tecartus
gptkb:Kymriah
gptkb:Yescarta
gptkb:Breyanzi
|
|
gptkbp:relatedTo
|
immuno-oncology
gene therapy
T-cell therapy
|
|
gptkbp:requires
|
leukapheresis
lymphodepleting chemotherapy
genetic modification of T cells
personalized manufacturing
|
|
gptkbp:sideEffect
|
neurotoxicity
cytokine release syndrome
|
|
gptkbp:usedFor
|
leukemia
B-cell lymphoma
hematologic malignancies
|
|
gptkbp:bfsParent
|
gptkb:cell_surface_receptor
gptkb:TCR
|
|
gptkbp:bfsLayer
|
6
|